Reorganization

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

By

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

By

The drugmaker is poised to cut 14 pipeline projects loose.

Novartis NY layoffs coming

Plans to unwind the Suffern, NY, site move forward this winter.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

By

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

Teva reorganizes

The company has created three new departments.

Eisai CEO retires

Lonnel Coats is leaving after 18 years with the company.

FDA overhaul coming

The agency is reorganizing and encouraging specialization.

Re-org for Actavis specialty brands business

The generics giant is splitting the business into four separate units with a newly appointed leader running each.

Layoff season continues

Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.

BMS managers get new jobs

The company's changes are no longer limited to R&D.

BMS narrows its R&D focus

BMS narrows its R&D focus

By

The company's pursuit of a tighter research focus follows a path very much like that of its peers.

Merck reorg reimagines sales force

Merck reorg reimagines sales force

By

The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.

Vivus pins Qsymia hopes on J&J vet after Zook steps down

Vivus pins Qsymia hopes on J&J vet after Zook steps down

By

J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.

Business briefs: Akorn, Bayer, Lonza, plus curbing CNS drug use

Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff

AstraZeneca reinforces oncology push

AstraZeneca reinforces oncology push

By

The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.

Pfizer offers timing for a split; earnings dip in Q2

By

Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.

Merck braces for revenue shortfall amid patent losses

By

Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.

Business briefs: Elan and Valeant

Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.

Business briefs: Roche, WellPoint, Bayer, Takeda, Allergan

A JAMA article says prostate cancer patients are getting treatments they don't need; Roche and AstraZeneca will share safety data; WellPoint gives cost sharing a new spin; Bayer seeks to boost its oncology pipeline; Takeda announces organizational changes; and the FDA puts Allergan's Restasis on track for generic competition.

R&D chief's spring-cleaning sweeps through Merck labs

By

Roger Perlmutter has begun to trim the fat off Merck's lackluster pipeline.

Astellas shutters OSI and Perseid, lets 200 US staff go in R&D reorg

Astellas shutters OSI and Perseid, lets 200 US staff go in R&D reorg

It was a particularly grim Monday for 200 Astellas employees in the US, who were informed that they were being let go and it was their last day with the company.

Patent losses stalk BMS, AZ quarterly results

By

Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets.

More pink slips at AstraZeneca

By

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.

AstraZeneca consolidates R&D, moves US commercial roles

AstraZeneca consolidates R&D, moves US commercial roles

By

AstraZeneca is cutting 650 jobs in the US, "primarily in R&D," and consolidating its R&D operations at three "strategic R&D centers" in "bioscience clusters," academic and industrial beehives where the company can tap into concentrations of talent and infrastructure.

AstraZeneca shakeup ousts commercial, R&D chiefs

AstraZeneca shakeup ousts commercial, R&D chiefs

By

AstraZeneca jettisoned its global head of commercial operations and R&D chief, eliminating their roles and curtly suctioning off the company's second-highest layer of management.

Boehringer bails out of virology R&D

Boehringer Ingelheim is getting out of virology and will shut down a Quebec research facility, eliminating 170 positions in the process.

Endo rebrands to move beyond roots in pain drugs

Endo rebrands to move beyond roots in pain drugs

By

Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.

J&J says no shakeup at McNeil Consumer Healthcare unit

By

J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.

Ipsen to bulk up commercial team as it moves US hub to NJ

By

Ipsen announced plans to reorganize its North American commercial operation by relocating the head office from California to New Jersey and hiring about 100 employees.

Digitas Health, Razorfish Health to share new leadership, global team, in efficiency-driven reorg

Digitas Health, Razorfish Health to share new leadership, global team, in efficiency-driven reorg

By

Digitas Health and Razorfish Health are undergoing an organizational restructure in which the two Publicis-owned siblings will share two newly appointed co-presidents, launch a single global leadership team and develop a variety of centers of excellence.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.